NASDAQ:CRDL Cardiol Therapeutics (CRDL) Stock Price, News & Analysis $2.26 -0.22 (-8.87%) (As of 03:57 PM ET) Add Compare Share Share Today's Range$2.24▼$2.5450-Day Range$1.83▼$2.4852-Week Range$0.66▼$3.12Volume404,256 shsAverage Volume397,551 shsMarket Capitalization$155.94 millionP/E RatioN/ADividend YieldN/APrice Target$8.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Cardiol Therapeutics alerts: Email Address Cardiol Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside277.2% Upside$8.75 Price TargetShort InterestHealthy1.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.50 out of 5 starsMedical Sector486th out of 927 stocksBiological Products, Except Diagnostic Industry79th out of 154 stocks 3.6 Analyst's Opinion Consensus RatingCardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiol Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cardiol Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.09% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiol Therapeutics has recently decreased by 3.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRDL. Previous Next 3.2 News and Social Media Coverage News SentimentCardiol Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cardiol Therapeutics this week, compared to 1 article on an average week.Search Interest10 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.49% of the stock of Cardiol Therapeutics is held by institutions.Read more about Cardiol Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -6.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -6.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 7.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiol Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone ResearchIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Cardiol Therapeutics Stock (NASDAQ:CRDL)Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Read More CRDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRDL Stock News HeadlinesSeptember 15 at 2:19 AM | americanbankingnews.comRoth Capital Comments on Cardiol Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:CRDL)September 13 at 8:28 PM | msn.comCardiol Therapeutics (CRDL) Upgraded to Buy: Here's WhySeptember 16, 2024 | Brownstone Research (Ad)Introducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.September 12, 2024 | americanbankingnews.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.75 Consensus Target Price from BrokeragesSeptember 11, 2024 | ca.finance.yahoo.comStocks in play: Cardiol Therapeutics IncSeptember 10, 2024 | proactiveinvestors.comCardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis studySeptember 7, 2024 | americanbankingnews.comCardiol Therapeutics (NASDAQ:CRDL) Shares Down 4.2% June 13, 2024 | proactiveinvestors.comCardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammationSeptember 16, 2024 | Brownstone Research (Ad)Introducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.May 22, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT flat on Friday (CRDL-WT-A)May 22, 2024 | investing.comCardiol Therapeutics Inc Class A (CRDL)May 14, 2024 | investorplace.comCRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024May 14, 2024 | proactiveinvestors.comCardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditisApril 2, 2024 | investorplace.comCRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023April 2, 2024 | proactiveinvestors.comCardiol Therapeutics surpasses enrollment goals, prepares for topline resultsMarch 16, 2024 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Friday (CRDL-WT-A)February 22, 2024 | benzinga.comCardiol Therapeutics Stock (NASDAQ:CRDL), Short Interest ReportFebruary 21, 2024 | proactiveinvestors.comCardiol Therapeutics wraps up patient enrollment for Phase II open label studySee More Headlines Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/16/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDL CUSIPN/A CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.75 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+273.9%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.65% Return on Assets-85.28% Debt Debt-to-Equity Ratio0.01 Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual Sales$60,000.00 Price / Sales2,690.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book7.31Miscellaneous Outstanding Shares68,998,000Free Float65,376,000Market Cap$161.46 million OptionableNot Optionable Beta0.89 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David G. Elsley MBAPresident, CEO & DirectorMr. Christopher J. Waddick C.A.C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & DirectorMr. Bernard Lim B.Sc.Chief Operating OfficerDr. Andrew Warwick Hamer M.D. (Age 62)Chief Medical Officer & Head of Research & Development Comp: $544.54kTrevor BurnsInvestor RelationsKey CompetitorsProKidneyNASDAQ:PROKReplimune GroupNASDAQ:REPLScholar RockNASDAQ:SRRKHumacyteNASDAQ:HUMACorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCBought 164,994 shares on 8/8/2024Ownership: 2.126%Foundations Investment Advisors LLCBought 48,000 shares on 8/2/2024Ownership: 0.069%Baader Bank AktiengesellschaftBought 29,028 shares on 7/17/2024Ownership: 0.042%Lion Street Advisors LLCBought 60,581 shares on 7/12/2024Ownership: 0.367%View All Institutional Transactions CRDL Stock Analysis - Frequently Asked Questions How have CRDL shares performed this year? Cardiol Therapeutics' stock was trading at $0.8432 at the beginning of 2024. Since then, CRDL shares have increased by 175.1% and is now trading at $2.32. View the best growth stocks for 2024 here. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) announced its earnings results on Monday, August, 12th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. Who are Cardiol Therapeutics' major shareholders? Top institutional investors of Cardiol Therapeutics include AdvisorShares Investments LLC (2.13%), Lion Street Advisors LLC (0.37%), Foundations Investment Advisors LLC (0.07%) and Baader Bank Aktiengesellschaft (0.04%). How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRDL) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
